主页 / 资源 / 网络研讨会 / 符合 Simcyp Simulator 系统认证监管要求的方法

符合 Simcyp Simulator 系统认证监管要求的方法

Live webinar

Physiologically-based pharmacokinetic (PBPK) modeling is being increasingly used in drug development to avoid unnecessary clinical drug–drug interaction (DDI) studies and inform drug labels.

Thus, regulatory agencies are recommending more rigorous demonstration of the prediction accuracy of PBPK platforms in their intended use. 

During the webinar, we will present a framework for qualification of the Simcyp Simulator with respect to competitive and mechanism-based CYP-mediated DDIs involving inhibition that was published recently (click on link below for our recent publication).

We will also discuss our strategy and ongoing qualification efforts for other key areas.    

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator – Kilford – – CPT: Pharmacometrics & Systems Pharmacology – Wiley Online Library

Register

Thank you for Registering!

Speakers
Bio Pic KarenYeo
Karen Rowland Yeo, PhD
Senior Vice President, Client & Regulatory Strategy
自 2002 年以来,Karen 一直负责与通过体外数据推断预测人体内药代动力学相关的项目。这包括在 Simcyp Simulator 中开发和实现模型。她的具体研究兴趣包括生理药代动力学建模和药物相互作用预测。
Certara Oliver H
Oliver Hatley
Senior Research Scientist
Oliver Hatley is a Senior Research Scientist who has been working at Certara since 2013. He obtained his PhD investigating in vitro-in vivo extrapolation of intestinal metabolism from the Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester. Oliver is part of the translational sciences in DMPK group within Simcyp and has lead development of the esterase organ and blood in vitro-in vivo scaling strategies. He is also involved in the development of special populations within the Simcyp Population-based Simulator.
返回顶部
Powered by Translations.com GlobalLink OneLink Software